Repros Therapeutics (RPRX)
Repros Therapeutics Revenues: 0.001M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
RPRX Revenues Rankings
| Overall | 0th percentile | 4423 of 4432 |
| Sector | 0th percentile | 471 of 471 in Healthcare |
| Industry | 0th percentile | 132 of 132 in Biotechnology |
RPRX Revenues Range, Past 5 Years
| Minimum | 0.001M | Jun 2009 |
| Maximum | 0.547M | Dec 2009 |
| Average | 0.1731M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these RPRX related companies
RPRX News
$RPRX will hold on just enough to convince u no sell off comin. when u least expect it, floor may become sinkhole.2 words: Liver Toxicity
about a day ago by ninanina65
about a day ago by ninanina65
FDA Says Repros Therapeutics (RPRX) Must Complete Integrated Safety Analysis of Oral Proellex
May 29, 4:03PM Street Insider
May 29, 4:03PM Street Insider
$RPRX - Trade Signal New - BTO @ 9.01-Limit w/6.55-Stop on the Wkly Chart w/.5N @ Risk http://chart.ly/8ac9pbe
about 4 days ago by TraderFoxxx
about 4 days ago by TraderFoxxx
RT @TechEdgeTrades $RPRX keep it on ur radar.Could move quickly. Something behind all the insider buying http://stks.co/3zt9 all over itTNX
about 6 days ago by Tango13
about 6 days ago by Tango13
$RPRX keep it on ur radar.Play it smart.Could move quickly. Something behind all the insider buying http://chart.ly/6sqfmh3
about 6 days ago by TechEdgeTrades
about 6 days ago by TechEdgeTrades
$RPRX Lots of insider buying.Short term tgt 11.10 Break res at 10.11 could make a quick move to 24 http://chart.ly/llny4yy
about 6 days ago by TechEdgeTrades
about 6 days ago by TechEdgeTrades
@YngvaiMalmsteve I see a record of a reverse split on Oct15 2010 chart shows a high of 57 on 8/31/07 $RPRX http://chart.ly/iac2rul
about 6 days ago by TechEdgeTrades
about 6 days ago by TechEdgeTrades
$RPRX saw that coming, but now will wait for the swing short, too focused w/ KV.A up 58% intraday
about 6 days ago by HighGrowthFinancial
about 6 days ago by HighGrowthFinancial
@TechEdgeTrades $RPRX wasn't truly a $54 stock back in 2007...it was actually around $15...it's just done some reverse splits
about 6 days ago by YngvaiMalmsteve
about 6 days ago by YngvaiMalmsteve
$RPRX was on my radar but didn't pull the trigger,MACD still diverging.Was $54 stock back in 2007 http://chart.ly/qiddnhn
about 6 days ago by TechEdgeTrades
about 6 days ago by TechEdgeTrades
Notable 52-Week Highs and Lows of the Day 05/25: (LCC) (RPRX) High; (DCTH) (MXWL) (VIP) Low
May 25, 3:09PM Street Insider
May 25, 3:09PM Street Insider
Unusual 11 Mid-Day Movers 05/25: (GNOM) (UPI) (RPRX) Higher; (TLB) (DCTH) (PAY) Lower
May 25, 1:42PM Street Insider
May 25, 1:42PM Street Insider
RT @slimtrader $RPRX - Looks like $GNOM setting up for a run on 5min chart < Told ya
about 7 days ago by slimtrader
about 7 days ago by slimtrader
VeriFone Systems, Quest Software, Other Stocks Hit 52-Week Highs Friday
May 25, 12:32PM Fox Business
May 25, 12:32PM Fox Business
$RPRX man thought this would have came back already,it will to,when?lesson not to short stocks that trade thin,this could see $10 easy
about 7 days ago by HighGrowthFinancial
about 7 days ago by HighGrowthFinancial
$GENE http://stks.co/3yyR $ROSG $GENE $RPRX $GNOM $TELK Full blog post here http://stks.co/3yyS
about 7 days ago by LincolnList
about 7 days ago by LincolnList
Repros Updates Special Protocol Assessment Documentation for Pivotal Studies for Androxal
May 22, 4:05PM Benzinga
May 22, 4:05PM Benzinga
Repros Updates Special Protocol Assessment Documentation for Pivotal Studies for Androxal(R)
May 22, 4:01PM GlobeNewswire
May 22, 4:01PM GlobeNewswire
Repros (RPRX) Gets Confirmation that Required Androxal Phase 3 Documents Delivered
May 16, 4:03PM Street Insider
May 16, 4:03PM Street Insider
FDA Receives Repros' Submission for Special Protocol Assessment Documentation for Pivotal Studies for Androxal(R)
May 16, 4:01PM GlobeNewswire
May 16, 4:01PM GlobeNewswire
Repros Therapeutics Inc.(R) Reports First Quarter 2012 Financial Results
May 15, 9:25AM GlobeNewswire
May 15, 9:25AM GlobeNewswire
Unusual 11 Mid-Day Movers 05/10: (ADY) (INSP) (RPRX) Higher; (SGI) (WFR) (ARX) Lower
May 10, 2:24PM Street Insider
May 10, 2:24PM Street Insider
Repros' Proellex(R)-V Clears Important Hurdle in Uterine Fibroid Program
Apr 30, 4:02PM GlobeNewswire
Apr 30, 4:02PM GlobeNewswire
Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year End 2011 Financial Results
Mar 27, 9:25AM GlobeNewswire
Mar 27, 9:25AM GlobeNewswire
Repros Therapeutics (RPRX) Announces FDA Meeting to Discuss Phase 3 Efficacy Studies of Androxal
Feb 27, 4:05PM Street Insider
Feb 27, 4:05PM Street Insider
FDA Grants Repros Meeting to Discuss Androxal(R) Phase 3 Study Design and Required Drug Dossier for NDA
Feb 27, 4:02PM GlobeNewswire
Feb 27, 4:02PM GlobeNewswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| RPRX | 8.34 | +0.07 | +0.85% | 122.23M |
| RPM | 26.36 | -0.02 | -0.08% | 3.463B |
| REFR | 3.39 | +0.07 | +2.11% | 62.78M |
| REE | 4.07 | -0.20 | -4.68% | 188.86M |
| REDF | 4.21 | -0.38 | -8.28% | 134.17M |
| RE | 102.12 | +0.90 | +0.89% | 5.440B |
| QPSA | 2.93 | -0.06 | -2.01% | 108.24M |
| QMM | 0.44 | +0.01 | +1.15% | 66.26M |
| QLTY | 10.62 | +0.23 | +2.21% | 280.22M |
| QLTI | 7.61 | +0.03 | +0.40% | 371.12M |